Beginner view — everything explained simply.
Machine-assisted translation — the German original version is authoritative.
Tissue & Regeneration
Pentadeca Arginate (PDA)
PDA · Pentadecapeptid-Arginat · BPC-157 Arginat · BPC-157 Arginatsalz · Pentadeca Arginate
Pentadeca Arginate (PDA) is marketed as a supposedly more stable arginate-salt variant of the pentadecapeptide BPC-157 (same 15-amino-acid sequence, merely an arginine counter-ion instead of acetate). For PDA itself there are – as of 2026 – no peer-reviewed human or even PDA-specific animal studies; the advertised higher stability is likewise not supported by independent, published data and stems from manufacturer/vendor material. Practically all findings cited in the advertising come from preclinical animal and in-vitro studies on BPC-157, not on PDA. PDA is not approved as a medicine and circulates as an experimental gray-market substance. This page is for information and context only – it is not a guide to use, dosing or acquisition.
Regulatory status
Not approved for humans
Not approved as a medicine – an experimental gray-market substance without clinical trials; the closely related BPC-157 is explicitly classified by authorities as not suitable for human use.
Drug class
Synthetic peptide derivative – advertised as the arginate salt of a BPC-157-related pentadecapeptide (15 amino acids). Not an approved active substance; no independent pharmacological characterization of PDA has been published.
Half-life (informative)
Not established for PDA; no published pharmacokinetic data. The advertised higher stability of the arginate salt is a vendor claim ("marketed as more stable") and is not supported by independent, peer-reviewed data.
Studied in the literature
There are practically no formal studies on PDA itself. Any applicable routes of administration come exclusively from BPC-157 research (in animal models, among others local/parenteral as well as oral administration; a few small human pilot trials of BPC-157 with intra-articular, intravesical or intravenous administration). These details describe only HOW research was conducted – they are explicitly not instructions for use.
Mechanism of action
An independent mechanism of action for PDA has not been investigated. PDA is marketed via the analogy to BPC-157: for BPC-157, preclinical models describe effects on angiogenesis (the formation of new blood vessels), growth factors (including VEGF) and the nitric oxide (NO) signaling pathway. Important: these mechanisms are (a) for BPC-157 predominantly from animal experiments and (b) for PDA pure hypothesis/advertising claim – not established and not proven in humans. Claim – not proven.
PDA and BPC-157 must not be equated: data on BPC-157 are not automatically transferable to the arginate salt. The identity, purity and actual salt/peptide content of products sold as "PDA" are generally unverified.
Research history
PDA emerged only recently in the biohacking and gray-market sphere, where it is advertised as the "next generation" or a more stable evolution of BPC-157. There has been no formal pharmaceutical development, clinical trial or regulatory assessment specifically for PDA; the marketing relies on the BPC-157 narrative and on stability promises that have not been independently verified.
Regulatory status by region
Neither PDA nor BPC-157 is approved as a medicine in the EU. As an experimental "research" peptide without marketing authorization, it lacks verified evidence of quality, efficacy and safety.
PDA is not FDA-approved. The related BPC-157 was classified by the FDA as a bulk substance with potential safety risks (503A compounding context: among other things possible immunogenicity depending on the route of administration, difficulties in characterizing peptide-related impurities/the active substance, as well as missing or only limited safety data). An FDA advisory committee is addressing the compounding status of BPC-157-related substances in 2026.
BPC-157 is on the WADA Prohibited List in category S0 (unapproved substances), prohibited at all times; PDA, as a BPC-157-related peptide, falls correspondingly under the same assessment. Anti-doping bodies explicitly warn about products sold as "for research purposes only."
Research areas
- Tissue repair and wound healing (advertised/derived from BPC-157 animal models – not proven for PDA)
- Tendon, ligament and musculoskeletal regeneration (predominantly preclinical on BPC-157; human data extremely sparse)
- Gastrointestinal protection/healing (preclinical BPC-157 findings; no PDA-specific data)
- Angiogenesis and vascular protection (mechanistic BPC-157 hypothesis – not confirmed in humans for PDA)
- Inflammation modulation (advertising claim by analogy to BPC-157 – not proven)
Documented effects (from the literature)
- For PDA itself there are no documented effects or adverse effects from controlled studies.
- For BPC-157, preclinical studies predominantly report no notable toxicities – but this concerns animal models, not humans and not PDA.
- The few small human pilot trials of BPC-157 (very small participant numbers, no robust efficacy data) do not permit any reliable safety statements.
Safety concerns & caution
- No human safety data for PDA; long-term effects entirely unknown.
- The identity, purity, peptide content and actual salt form of products sold as "PDA" are regularly unverified.
- Possible immunogenicity and peptide-related impurities were named by the FDA as open risks for the related BPC-157.
- Transferring BPC-157 animal data to PDA in humans is scientifically not permissible.
Risks of gray-market purchase
- Sold as "research peptide / not for human use" while being de facto advertised for self-administration.
- Possible contaminants (e.g. bacterial endotoxins/LPS), mislabeling, deviating or absent active-substance content.
- Conflation of BPC-157 hype and PDA: preclinical BPC-157 claims are presented as proven PDA effects – this is misleading.
- Uncontrolled quality without pharmaceutical testing; stability/efficacy promises not independently verified.
- Athletes risk anti-doping violations (WADA S0).
Frequently asked questions
Is the effect of Pentadeca Arginate (PDA) scientifically proven?
No. As of 2026 there are no peer-reviewed human or PDA-specific animal studies demonstrating a benefit of PDA. The effects cited in the advertising come from preclinical research on BPC-157 and are not transferable to PDA or to humans. Advertised benefits are to be understood as claims, not as proven facts.
Is PDA the same as BPC-157?
Not quite. PDA is advertised as the arginate salt of the same 15-amino-acid peptide (same sequence, a different counter-ion than the usual acetate). Even if the sequence is identical, the data gathered for BPC-157 – which are in any case predominantly from animal experiments – are not automatically transferable to the PDA variant. Independent studies on PDA are lacking.
Is it true that PDA is "more stable" than BPC-157?
That is a vendor claim, not an independently verified finding. Statements such as a many-fold higher stability of the arginate salt come from manufacturer/distributor material and have so far not been confirmed in independent, peer-reviewed publications.
Is PDA approved as a medicine?
No. PDA is approved as a medicine neither in the EU nor in the USA and is regarded as an experimental gray-market substance. The closely related BPC-157 is explicitly not recommended by authorities for human use and is banned in sport (WADA, category S0).
What does this page explicitly point out?
This page is purely informational and assesses the state of the evidence. It contains no dosing, use, preparation or acquisition information. Statements on routes of administration describe exclusively how research was conducted (on BPC-157) and do not constitute instructions for use.
Sources
Primary and reference sources for your own reading.
- U.S. Anti-Doping Agency (USADA)BPC-157: Experimental Peptide Creates Risk for Athletes (S0, WADA-Verbot; nicht für menschliche Anwendung) – betrifft BPC-157, nicht PDA-spezifisch
- Pharmaceuticals (Basel) 2024, PMC11053547The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity (Mechanismen: NO-System, VEGF/Angiogenese; überwiegend präklinisch) – BPC-157, nicht PDA-spezifisch
- Pharmaceuticals (Basel) 2025, PMC11859134Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review (Studien überwiegend an Tiermodellen; nicht als Arzneimittel verschrieben, am Schwarzmarkt verfügbar) – BPC-157, nicht PDA-spezifisch
- Current Reviews in Musculoskeletal Medicine 2025, PMC12446177Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Humandaten äußerst spärlich, nur wenige Pilotstudien; nicht für klinischen Einsatz empfohlen) – BPC-157, nicht PDA-spezifisch
Related substances
Unfamiliar terms? Look them up in the glossary or read the fundamentals.
This profile is for information and education only. It is not medical advice and deliberately contains no dosing or usage details. Decisions about use belong in a doctor’s hands.